Lupus Research Alliance Prompted Stelara® Study for Lupus --
Results Show Potential for New Treatment Option!
We are excited to share new data from a Phase 2 study that showed significant benefit for lupus. The investigational results for Stelara® were issued by Janssen Research & Development, LLC during the American College of Rheumatology meeting that is currently taking place in San Diego. Stelara® is not approved for the treatment of lupus, but is approved by the FDA for certain autoimmune diseases.
In 2013, our legacy organizations Alliance for Lupus Research and Lupus Research Institute initiated an ongoing drug repurposing effort to identify potential lupus treatments among medications approved for certain other autoimmune diseases. After a comprehensive review, Stelara® was our No. 1 pick among biologics. Based on this work and the need for improved care, we encouraged Janssen to test Stelara® for lupus.
As noted in Janssen’s press release, "The Lupus Research Alliance advocated for investigating Stelara® in SLE given the limited treatment options and the high unmet medical need for patients."
We encouraged Janssen to test Stelara® for lupus, and the company subsequently opened a Phase 2 global trial in 2015.
Because of the positive Phase 2 results, Janssen has also announced plans to further test Stelara® in Phase 3 trials.
“The positive Phase 2 results and initiation of Phase 3 development bring the hope of a new treatment closer,” noted Kenneth M. Farber, President and CEO of the Lupus Research Alliance. “We are particularly pleased about the promise of Stelara®, having recognized its potential in lupus early on.”
Learn more about Stelara® as a possible future treatment for lupus.
Stelara® is a registered trademark of Janssen Biotech, Inc.
| 
